Outset Medical Competitors

Outset Medical (NASDAQ:OM) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Valuation and Earnings

This table compares Outset Medical and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

Outset Medical has higher earnings, but lower revenue than LivaNova.

Profitability

This table compares Outset Medical and LivaNova's net margins, return on equity and return on assets.

Insider & Institutional Ownership

84.6% of Outset Medical shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Outset Medical and LivaNova, as provided by MarketBeat.com.

Outset Medical presently has a consensus target price of $56.50, indicating a potential upside of 3.67%. LivaNova has a consensus target price of $69.3333, indicating a potential downside of 14.79%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts plainly believe Outset Medical is more favorable than LivaNova.

Summary

LivaNova beats Outset Medical on 5 of the 9 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Valuation & Earnings

This table compares Outset Medical and CONMED's top-line revenue, earnings per share (EPS) and valuation.

CONMED has higher revenue and earnings than Outset Medical.

Profitability

This table compares Outset Medical and CONMED's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Outset Medical and CONMED, as provided by MarketBeat.com.

Outset Medical presently has a consensus target price of $56.50, indicating a potential upside of 3.67%. CONMED has a consensus target price of $104.60, indicating a potential downside of 19.82%. Given Outset Medical's higher possible upside, equities research analysts clearly believe Outset Medical is more favorable than CONMED.

Insider and Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CONMED beats Outset Medical on 6 of the 8 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Valuation and Earnings

This table compares Outset Medical and InMode's top-line revenue, earnings per share (EPS) and valuation.

InMode has higher revenue and earnings than Outset Medical.

Profitability

This table compares Outset Medical and InMode's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Outset Medical and InMode, as provided by MarketBeat.

Outset Medical currently has a consensus target price of $56.50, indicating a potential upside of 3.67%. InMode has a consensus target price of $71.50, indicating a potential downside of 14.40%. Given Outset Medical's higher possible upside, research analysts plainly believe Outset Medical is more favorable than InMode.

Insider & Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

InMode beats Outset Medical on 5 of the 7 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Insider & Institutional Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Outset Medical and BioLife Solutions' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Outset Medical and BioLife Solutions' top-line revenue, earnings per share (EPS) and valuation.

Outset Medical has higher earnings, but lower revenue than BioLife Solutions.

Analyst Recommendations

This is a breakdown of current recommendations for Outset Medical and BioLife Solutions, as provided by MarketBeat.

Outset Medical currently has a consensus target price of $56.50, indicating a potential upside of 3.67%. BioLife Solutions has a consensus target price of $46.6667, indicating a potential upside of 38.93%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts plainly believe BioLife Solutions is more favorable than Outset Medical.

Summary

BioLife Solutions beats Outset Medical on 8 of the 9 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 84.6% of Outset Medical shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Natus Medical and Outset Medical, as reported by MarketBeat.com.

Outset Medical has a consensus price target of $56.50, indicating a potential upside of 3.67%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts plainly believe Outset Medical is more favorable than Natus Medical.

Profitability

This table compares Natus Medical and Outset Medical's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Natus Medical and Outset Medical's gross revenue, earnings per share and valuation.

Outset Medical has lower revenue, but higher earnings than Natus Medical.

Summary

Natus Medical beats Outset Medical on 5 of the 9 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Insider & Institutional Ownership

78.4% of AxoGen shares are held by institutional investors. Comparatively, 84.6% of Outset Medical shares are held by institutional investors. 6.9% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares AxoGen and Outset Medical's revenue, earnings per share and valuation.

Outset Medical has lower revenue, but higher earnings than AxoGen.

Profitability

This table compares AxoGen and Outset Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AxoGen and Outset Medical, as provided by MarketBeat.

AxoGen presently has a consensus target price of $23.75, indicating a potential upside of 22.30%. Outset Medical has a consensus target price of $56.50, indicating a potential upside of 3.67%. Given AxoGen's stronger consensus rating and higher probable upside, research analysts plainly believe AxoGen is more favorable than Outset Medical.

Summary

Outset Medical beats AxoGen on 5 of the 9 factors compared between the two stocks.